The transplantable EMT6 mouse breast cancer line expresses low levels of CD200 in vitro, but upregulates CD200 following inoculation into immunocompetent mice (194); this is similar to PD-L1, which is often expressed at low levels in vitro, but rapidly upregulated in immune active environments. Here, CD274 is linked to breast carcinoma.